solifenacin accord 5 mg apvalkotās tabletes
accord healthcare b.v., netherlands - solifencīna sukcināts - apvalkotā tablete - 5 mg
vesicare 1 mg/ml suspensija iekšķīgai lietošanai
astellas pharma d.o.o., slovenia - solifencīna sukcināts - suspensija iekšķīgai lietošanai - 1 mg/ml
tamisten 5 mg apvalkotās tabletes
medochemie ltd., cyprus - solifencīna sukcināts - apvalkotā tablete - 5 mg
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatīts, atopisks - citi dermatoloģiski preparāti - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
gardurin 5 mg apvalkotās tabletes
farmaprojects s.a.u, spain - solifencīna sukcināts - apvalkotā tablete - 5 mg
gardurin 10 mg apvalkotās tabletes
farmaprojects s.a.u, spain - solifencīna sukcināts - apvalkotā tablete - 10 mg
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēma, - mutes trakta kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
belara 0,03 mg/2 mg apvalkotās tabletes
gedeon richter plc., hungary - ethinylestradiolum, chlormadinoni acetas - apvalkotā tablete - 0,03 mg/2 mg
clormetin 2 mg/0,03 mg apvalkotās tabletes
exeltis baltics uab, lithuania - chlormadinoni acetas, ethinylestradiolum - apvalkotā tablete - 2 mg/0,03 mg